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1 Introduction
A decrease in the incidence of respiratory distress
syndrome (RDS) in the newborn following mater-
nal glucocorticoid treatment has been documented
by LlGGINS and HOWIE [20, 21], and confirmed
by others [5, 8, 23, 29]. Experimental studies have
shown that glucocorticoid therapy stimulates the
synthesis [1, 25-27] and secretion [9, 10, 24] of
the major surfactant component, disaturated
lecithin.
Beta-sympathomimetic drugs are widely used
to prevent premature uterine activity. These
drugs cross the placenta [30] and may thus affect
fetal organs including the lung. Following beta-
sympathomimetic drug administration in pre-
mature labor, the incidence of RDS has been
reported to increase [7], to decrease [6], or to
remain unaltered [20]. Beta-sympathomimetic
stimulation increases the secretion of surfactant
from its intracellular storage in adults [22] and in
fetuses [9, 11, 32]. In addition, a beta-sympatho-
mimetic drug decreases the secretion rate of fetal
lung fluid [31]. In the present study we have
investigated the effect of a glucocorticoid agent
and a beta-sympathomimetic drug on the phos-
Tab. I. Protocol of the drug treatments
Drug Dosage Age and Route of Administration Time of Evaluation
A. Betamethasone 0.24 mg Intramuscularly to 26.8 day-old fetus
B. None
Five min from delivery, day 28.7


















the doe, days 26.8-28.5
Intramuscularly to 27.8 day-old fetus,
2nd time intraperitoneally to 28.7 day-old
fetus at delivery
Intraperitoneally to 28.7 day-old fetus
at delivery
Five min from delivery, day 28.7
Five min from delivery, day 28.7.
Littermate to C.
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pholipids of the alveolar lavage fluid from pre-
mature rabbits in order to evaluate whether both
these drugs accelerate fetal lung maturation.
2 Materials and methods
New Zealand albino rabbits were used. The time of
conception was known within ± 4 hours. The
protocols for the administration of the drugs are
shown in Tab. I. The number of fetuses (does) in
each study group was as follows: A: 34 (20); B: 63
(20); C: 16 (8); D: 55 (8); E: 20 (3); F: 25 (4);
G: 20 (10); H: 27 (10). The pregnant does were
operated upon under local anesthesia using 3—4 ml
of 0.25% of lidocaine without adrenalin. Beta-
methasone sodium phosphate (0.12mg) and beta-
methasone acetate (0.12mg) (Celestone Chrono-
dose®, Schering Corp), ritodrine hydrochloride
(0.5 mg) (Utopar®, Ferrosan), or 0.9% saline were
given intramuscularly in 0.05 ml to the fetus.
Following the drug injections, 0.02—0.03 ml of
barium sulfate was injected intramuscularly, in
order to identify the drug-exposed fetuses by
radiography after the experiment. One to two
fetuses received the injection and the littermates
served as controls. Th?( fetuses were removed
from the uterus by cesarean section under local
anesthesia, and the umbilical cord was cut. The
position of the individual fetuses in the uterine
horns was identified. The newborn animals were
kept in room air at 25 °C, and were allowed to
breathe for 5 or 30 minutes (Tab. I).
Following the intracerebral injection of 0.1 ml
of phenobarbital, the airways were lavaged as
described previously [15]. The total lipid fraction
was isolated according to BLIGH and DYER [4].
An aliquot was taken for analysis of disaturated
phosphatidylcholine [15]. The rest were analyzed
by two-dimensional thin-layer chromatography
and the individual phospholipids were quantified
by measuring their phosphorus contents [15]. For
each phospholipid analysis, lavages from three
to four fetuses were pooled. The results were
expressed as the mean ± SEM, and the statistical
significance was calculated using the t-test.
3 Results
3.1 Effect of glucocorticoid treatment: Beta-
methasone administration decreased the body
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1
 The treatment protocols are shown in Tab. I: A, B, and C.
2
 The sum of phosphatidylcholine, phosphatidylinositol, phosphatidylserine, phosphatidylethanolamine, bis-(mono-
acylglycerol) phosphate, phosphatidylglycerol, and Sphingomyelin.
3
 Mean ± SEM (number of analyses).
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weight (betamethasone: 29.3 ± 0.6 g; littermate
control: 34.0 ± 0.5 g, p < 0.001), and the dry
weight of the lungs (0.202 ± 0.008 g; control:
0.241 ±0.010g, p < 0.02). There was no signifi-
cant difference in the lung dry weight/total body
weight ratio as compared between the two groups
(0.0065 ± 0.0003, control: 0.0066 ±0.0006). Injec-
tion of saline and barium sulfate to the fetus had
no effect on the body or lung weights of the fetus
(data not shown).
The recovery of the phospholipids in alveolar lavage
following betamethasone treatment is shown in
Tab. if except the data for phosphatidylglycerol,
phosphalidylethanolamine, and bis- (monoacyl·
glycerol) phosphate. Betamethasone significantly
increased the recovery of total phospholipid, phos-
phatidylcholine, disaturated phosphatidylcholine
and phosphatidylinositol as compared to litter-
mate controls, and increased disaturated phos-
phatidylcholine and phosphatidylinositol as com-
pared to saline treated controls. The drug had no
significant effect on the other phospholipids.
The effect of betamethasone on the phospho-
lipid composition is shown in Tab. I I I . The drug
increased disaturated phosphatidylcholine/sphingo-
myelin ratio and phosphatidylinositol. In addition,
betamethasone decreased phosphatidylserine as
compared to littermate controls. Saline injection
to the fetus had no significant effect on the
quality or quantity of alveolar lavage phospho-
lipids, as compared to the littermatcs (data not
shown).
3.2 Effect of beta-sympathomimetic drug treat-
ment: A low dose of ritodrine, injected into the
doe, had no effect on either the various phospho-
lipid fractions of the alveolar lavage (Tab. IV), or
the recovery of total phospholipid (ritodrine:
5.3 ± 0.8 nmoles/g body weight; saline-control:
5.1 ± 0.6 nmoles/g body weight), or the recovery
of individual phospholipids (data not shown).
In another experiment, ritodrine was given directly
to the fetus and to the premature newborn at
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 The treatment protocols are shown in Tab. I: A, B, and C.
2
 Mean ± SEM (number of analyses).
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birth. The littermates that received ritodrine at choline and phosphatidylinositol. As shown by
birth served as controls (Tab. I: G, H). Ritodrine FELDMAN et al., only phds^hatidylglycerol exceeds
administration to the fetus and to the newborn the capacity of phosphatidylinositol to activate
significantly decreased the recovery of phosphat- lung phosphocholine cytidyltransferase which pre-
idylinositol (0.42 ± 0.04 nmoles/g body weight; sumably is a rate limiting enzyme in phosphatidyl·
control, ritodrine at birth: 0.58 ± 0.04 nmoles/g choline synthesis [12]. In addition, both phosphat-
body weight, p < 0.02), but had no significant idylglycerol and phosphatidylinositol promote the
effect on the total phospholipid recovery absorption of disaturated phosphatidylcholine
(4.9 ± 0.3 nmoles/g body weight; control: from subphase to the surface [17]. This is impor-
5.4 ± 0.3 nmoles/g body weight), or on the other tant in terms of surfactant function [2]. Therefore,
phospholipids (data not shown). Ritodrine admin- the observed increase in surfactant phosphatidyl-
istration to the fetus decreased phosphatidylinosi- inositol seems to explain further the mechanism
tol/sphingomyelin and disaturated phosphatidyl· of glucocorticoids in accelerating the lung matura-
choline/sphingomyelin ratios (Tab. V). The drug tion and preventing RPS.
did not alter the total body weight or the dry Beta-sympatomimetic drugs may improve neonatal
weight of the lung (data not shown). respiratory adaptation by decreasing fetal lung
Ritodrine given to the fetus and at birth (group fluid secretion [18, 31] or by promoting the secre-
' G) decreased phosphatidylinositol/sphingomyelin tion of lung surfactant [11, 32].
(p < 0.02), and disaturated phosphatidylcholine/ It has been proposed that both glucocorticoids and
sphingomyelin ratios (p < 0.05), as compared to sympathomimetic drugs affect lung maturation by
the offspring of the saline treated does (group F). a mechanism, that increases intracellular cyclic
The lavage phospholipids in the newborns that AMP [3]. However, it is unlikely that the gluco-
were treated with ritodrine at birth (group H) were corticoid effect is solely based upon interaction
not significantly different from phospholipids in with cyclic AMP system [14].
the offspring of the saline treated does (group F). We found that ritodrine did not increase surfactant,
when given at birth. Since beta-sympatomimetic
drugs acutely increase surfactant secretion in the
rabbit fetus of comparable gestational age [1 1 , 30]
4 Discussion
 it ^ ukel ^ &β Jack of e£fect at birth was due
In the present study it was demonstrated that to high endogenous adrenergic activity. On the
betamethasone administration to the immature other hand the failure of maternal ritodrine to
fetus increases both surfactant phosphatidyl- affect fetal surfactant phospholipids may be solely
Tab. IV. Effect of maternal ritodrine on the phospholipid composition of the lavage fluid.
Group Ε' Group F1
Ritodrine Saline control
Phosphatidylcholine 70.2 ± 0.9 % (6)2 69.9 ± 2.9 % (8)2
Phosphatidylinositol 9.3 ± 0.8% 9.0 ± 1.3%
Phosphatidylglycerol 0.4 ± 0.1 % 0.6 ± 0.1 %
Phosphatidylserine 2.6 ± 0.3 % 2.9 ± 0.1 %
Phosphatidylethanolamine 4.8 ± 0.5 % 4.8 ± 0.4%
Bis-(monoacylglycerol) phosphate 0.4 ± 0.0% 0.3 ± 0.1 %
Sphingomyelin 12.3 ±2 .2% 12.5 ±0.9%
Total 100 % 100 %
Phosphatidylinositol/sphingomyelin ratio 0.8 ± 0.05 0.8 ± 0.1
Disaturated phosphatidylcholine sphingomyelin ratio 2.7 ± 0.6 2.6 ± 0.2
1
 The treatment protocols are shown in Tab. I: E and F.
2
 Mean ± SEM (number of analyses).
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Tab. V. The phospholipid composition of the lavage fluid after ritodrine to the fetus.
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69.4 ± 2.3 % (7)2
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0.6 ±0.1%
2.4 ± 0.3 %










 The treatment protocols are shown in Tab. I, G and H.
2
 Mean ± SEM (number of analyses).
due to the low dose of the drug. The decrease in
disaturated phosphatidylcholine/sphingomyelin
ratio and phosphatidylinositol following the high
dose of ritodrine (Tab. V) can be due to premature
release of surfactant to fetal lung fluid without a
compensatory increase in surfactant synthesis
[14, 16], or due to beta-sympathomimetic-induced
hyperinsulinemia and hyperglycemia [28].
The present and previous results demonstrate that,
depending on the dosage and time of administra-
tion, beta-adrenergic drugs may increase, decrease,
or have little effect on the surfactant secretion.
This helps to explain the controversy concerning
the influence of the sympathomimetic drugs on
the incidence of RDS [6, 7, 20]. Since labor may
be associated with acceleration of lung maturation
[13], and beta-sympathomimetics delay the pre-
mature delivery in some cases, the present data
does not contradict the use of small to moderate
doses of beta-adrenergic drugs in threatened pre-
mature labor.
Summary
Beta-sympathomimetic drugs and glucocorticoid agents
are given in preterm labor to prevent severe consequences
of prematurity. It is unclear whether beta-sympatho-
mimetics accelerate lung maturation, or whether they
only tend to delay preterm delivery. We have evaluated
the effects of betamethasone and ritodrine in rabbits on
alveolar lavage phospholipids in premature rabbits, a mean
of 28.7 days from conception. Betamethasone given to
26-day-old fetuses increased the surfactant phospholipids,
phosphatidylinositol and disaturated phosphatidylcholine;
increased disaturated phosphatidylcholine/sphingomyelin
ratio, and phosphatidylinositol (percent of phospho-
lipids), as compared to untreated littermates, or to saline
treated controls. A low dose of ritodrine given to the
pregnant doe, and a high dose given at premature birth
had no detectable effects on alveolar lavage phospholipids.
However, a high dose of ritodrine given one day before
the delivery to the fetus and at premature birth decreased
the disaturated phosphatidylcholine/sphingomyelin ratio
and phosphatidylinositol in alveolar lavage. While gluco-
corticoid administration increases the synthesis and secre-
tion of surfactant phospholipids, a high dose of a beta-
sympathomimetic drug may decrease the surfactant.
However, spontaneous premature labor is associated with
accelerated lung maturation, and accordingly the present
results do not contradict the use of a low dosage of beta-
sympathomimetic drug to delay preterm delivery.
Keywords: Betamethasone, lecithin/sphingomyelin ratio, lung surfactant, phosphatidylcholine, phosphatidylinositol,
preterm infant, respiratory distress syndrome, ritodrine.
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Zusammenfassung
Einfluß von Betamethason und Ritodrin auf die Sekretion
des Lungensurfactant beim Feten
Bei Frühgeburten werden Betasympathomimetika und
Glukokortikoide zur Vermeidung durch Unreife bedingter
schwerer Komplikationen verabreicht. Es ist nicht geklärt,
ob Betasympathomimetika die Lungenreifung beschleuni-
gen oder ob sie lediglich die Frühgeburt verzögern. Wir
untersuchten den Einfluß von Betamethason und Ritodrin
auf die Phospholipide in der Alveolarlavage bei früh-
geborenen Kaninchen, die im Durchschnitt 28,7 Tage post
conceptionem geboren wurden. Wurde bei einer Tragzeit
von 26 Tagen Betamethason verabreicht, kam es zu einem
Anstieg der Oberflächenphospholipide/Phosphatidylinosi-
tol und des doppelgesättigten Phosphatidylcholins. Auch
die Phosphatidylcholin/Sphingomyelin-Ratio wie auch das
Phosphatidylinositol (in % der Phospholipide) stieg im
Vergleich zu unbehandelten bzw. mit NaCl behandelten
Kontrolltieren. Eine dem trächtigen' Muttertier ver-
abreichte niedrige Ritodrindosis wie auch eine hohe Dosis,
die in der Phase der Frühgeburt gegeben wurde, hatten
keinen nachweisbaren Einfluß auf die Phospholipide in
der Alveolarlavage. Wurde Ritodrin jedoch in hoher Dosie-
rung einen Tag vor der Geburt an den Feten sowie bei der
Frühgeburt verabreicht, kam es zu einem Abfall der Ratio
von doppelgesättigten Phosphatidylcholinen und Sphingo-
myelinen sowie des Phosphatidyünositols in der Aleolar-
lavage. Während Glukokortikoide die Synthese und Sekre-
tion von oberflächenaktiven Phospholipiden stimulieren,
haben Betasympathomimetika in hoher Dosierung einen
gegenteiligen Effekt. Eine spontane Frühgeburt geht
jedoch mit einer beschleunigten Lungenreifung einher.
Die vorliegenden Ergebnisse sprechen nicht gegen den
Einsatz von Betasympathomimetika in niedriger Dosie-
rung zur Verzögerung einer Frühgeburt.
Schlüsselwörter: Betamethason, Frühgeborenes, Lezithin/Sphingomyelin-Ratio, Lungensurfactant, Phosphatidylcholin,
Phosphatidylinositol, respiratorisches Distress-Syndrom, Ritodrin.
Resume
Effets de la betamethasone et de la ritodrine sur la secre-
tion du surfactant pulmonaire chez la foetus
On utilise les betamimetiques et les glucocorticoi'des au
cours de l'accouchement premature pour eviter les con-
sequences severes de la prematurite. On ne sait pas pre-
cisement si les betamimetiques accelerent la maturation
pulmonaire, ou si ils retardent seulement le terme de
l'accouchement premature.
Nous avons determine les effets de la betamethasone et de
la ritodrine sur les phospholipides alveolaires receuillis par
lavage chez les lapins prematures,nes en moyenne 28,7 jours
apres la conception. La betamethasone, donnee aux foetus
de 26 jours augmente les phospholipides du surfactant,
Phosphatidylinositol et phosphatidylcholine disature; le
rapport phosphatidylcholine disature sur sphingomyeline
et le phosphatidyl Inositol (% de phospholipides) sont
augmentes par rapport aux autres membres de la portee
non traites ou aux temoins traites par du serum sale. Une
faible dose de ritodrine administree ä la lapine ou une
forte dose administree lors de l'accouchement premature
n'a pas d'effet detectable sur les phospholipides alveo-
laires obtenus par lavage.
Toutefois. une dose elevee de ritodrine, administree au
foetus un jour avant la naissance et lors de l'accouche-
ment premature, diminue le rapport phosphatidylcholine
disature sur sphingomyeline et le Phosphatidylinositol du
liquide de lavage alveolaire. Alors que les glucocorti-
co'ides augmentent la synthese et la secretion des phos-
pholipides du surfactant, une dose elevee de betamime-
tique peut diminuer le surfactant.
Neanmoins, l'accouchement premature spontane s'accom-
pagne d'uue acceleration de la maturation pulmonaire et
en outre, nos resultats ne contre-indiquent pas l'utilisa-
tion des betamimetiques ä doses faibles dans le but de
retarder l'accouchement premature.
Mots-cles: Betamethasone, phosphatidylcholine, Phosphatidylinositol, prematures, rapport lecithine/sphingomyeline,
ritodrine, surfactant pulmonaire, syndrome de detresse respiratoire.
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This book presents a comprehensive and updated catalogue of the already
large, and rapidly growing number of chromosome aberrations in man. A first
section introduces the reader to cytogenetic nomenclature, the normal human
karyotype, clinical and epidemiologic features and formation of chromosome
aberrations. It is followed by chapters on aberrations of chromosomes 1-22, X, Y,
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The book is completed by three indices: a list of genes mapped to
chromosomes or chromosomal segments, an index of malformations and




de Gruyter · Berlin · New York
